Nanotechnology-based detection and targeted therapy in cancer: Nano-bio paradigms and applications

Cancers

Volumn 3, Issue 3, 2011, Pages 2888-2903

  Mousa, Shaker A ^a,b   Bharali, Dhruba J ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Dendrimer; Early detection; Nanomedicine; Nanoparticles; Oncology; PLGA; Quantum dots; Site directed delivery; Therapy

Indexed keywords

CISPLATIN; DENDRIMER; DOXORUBICIN; FERUCARBOTRAN; GENEXOL PM; GOLD NANOSHELL; IRON OXIDE; MAGNETIC NANOPARTICLE; NANOCELL; NANOCRYSTAL; NANOPARTICLE; NANOSHELL; PACLITAXEL; POLYGLACTIN NANOPARTICLE; QUANTUM DOT; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ACCURACY; ACUTE TOXICITY; BREAST CANCER; CANCER DIAGNOSIS; COLON CANCER; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MONITORING; HUMAN; IMAGING SYSTEM; LIVER METASTASIS; MEAN RESIDENCE TIME; METASTASIS; MOLECULARLY TARGETED THERAPY; NANOENCAPSULATION; NANOFORMULATION; NANOMEDICINE; NEPHROTOXICITY; NONHUMAN; REVIEW; SUSTAINED DRUG RELEASE; TISSUE ENGINEERING;

EID: 80053196367     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3032888     Document Type: Review

References (70)

1. NNI. What is nanotechnology? Available online: http://www.nano.gov/nanotech-101/what/definition (accessed on July 14 2011).
2. Garcia, M. Jemal A.; Ward, E.M. Center, M.M.; Hao, Y.; Siegel, R.L.; Thun, M.J. Global Cancer Facts & Figures; The American Cancer Society: Atlanta, GA, USA, 2007.
3. Stobbe, M. Cancer to Be World's Top Killer by 2010: WHO Says; AFP: Washington, USA, Tuesday, 9th December 2008.
4. Cuenca, A.G.; Jiang, H.; Hochwald, S.N.; Delano, M.; Cance, W.G.; Grobmyer, S.R. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 2006, 107, 459-466.
5. Bharali, D.J.; Lucey, D.W.; Jayakumar, H.; Pudavar, H.E.; Prasad, P.N. Folate-receptor-mediated delivery of InP quantum dots for bioimaging using confocal and two-photon microscopy. J. Am. Chem. Soc. 2005, 127, 11364-11371.
6. Gao, X.; Cui, Y.; Levenson, R.M.; Chung, L.W.; Nie, S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 2004, 22, 969-976.
7. Michalet, X.; Pinaud, F.F.; Bentolila, L.A.; Tsay, J.M.; Doose, S.; Li, J.J.; Sundaresan, G.; Wu, A.M.; Gambhir, S.S.; Weiss, S. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005, 307, 538-544.
8. Howarth, M.; Takao, K.; Hayashi, Y.; Ting, A.Y. Targeting quantum dots to surface proteins in living cells with biotin ligase. Proc. Natl. Acad. Sci. USA 2005, 102, 7583-7588.
9. Smith, A.M.; Dave, S.; Nie, S.; True, L.; Gao, X. Multicolor quantum dots for molecular diagnostics of cancer. Expert Rev. Mol. Diagn. 2006, 6, 231-244.
10. Stroh, M.; Zimmer, J.P.; Duda, D.G.; Levchenko, T.S.; Cohen, K.S.; Brown, E.B.; Scadden, D.T.; Torchilin, V.P.; Bawendi, M.G.; Fukumura, D.; Jain, R.K. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat. Med. 2005, 11, 678-682.
11. Lidke, D.S.; Nagy, P.; Heintzmann, R.; Arndt-Jovin, D.J.; Post, J.N.; Grecco, H.E.; Jares-Erijman, E.A.; Jovin, T.M. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat. Biotechnol. 2004, 22, 198-203.
12. Medintz, I.L.; Uyeda, H.T.; Goldman, E.R.; Mattoussi, H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat. Mater. 2005, 4, 435-446.
13. Wu, X.; Liu, H.; Liu, J.; Haley, K.N.; Treadway, J.A.; Larson, J.P.; Ge, N.; Peale, F.; Bruchez, M.P. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat. Biotechnol. 2003, 21, 41-46.
14. Bagalkot, V.; Zhang, L.; Levy-Nissenbaum, E.; Jon, S.; Kantoff, P.W.; Langer, R.; Farokhzad, O.C. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano. Lett. 2007, 7, 3065-3070.
15. LaRocque, J.; Bharali, D.J.; Mousa, S.A. Cancer detection and treatment: the role of nanomedicines. Mol. Biotechnol. 2009, 42, 358-366.
16. Bharali, D.J.; Dier, U.; Davis, P.J.; Mousa, S.A. Tetrac-Conjugated Quantum Dots for Diagnosis and Treatment of Pancreatic Cancer: An In vitro Evaluation Immunol. Endocr. Metabol. Agents Med. Chem. 2009, 9, 5.
17. Frangioni, J.V. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 2003, 7, 626-634.
18. Gao, J.; Chen, X.; Cheng, Z. Near-infrared quantum dots as optical probes for tumor imaging. Curr. Top Med. Chem. 2010, 10, 1147-1157.
19. Parungo, C.P.; Ohnishi, S.; Kim, S.W.; Kim, S.; Laurence, R.G.; Soltesz, E.G.; Chen, F.Y.; Colson, Y.L.; Cohn, L.H.; Bawendi, M.G.; Frangioni, J.V. Intraoperative identification of esophageal sentinel lymph nodes with near-infrared fluorescence imaging. J. Thorac. Cardiovasc. Surg. 2005, 129, 844-850.
20. Allen, P.M.; Liu, W.; Chauhan, V.P.; Lee, J.; Ting, A.Y.; Fukumura, D.; Jain, R.K.; Bawendi, M.G. InAs(ZnCdS) quantum dots optimized for biological imaging in the near-infrared. J. Am. Chem. Soc. 2010, 132, 470-471.
21. Shubayev, V.I.; Pisanic, T.R., 2nd; Jin, S. Magnetic nanoparticles for theragnostics. Adv. Drug Deliv. Rev. 2009, 61, 467-477.
22. Sun, C.; Lee, J.S.; Zhang, M. Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliv. Rev. 2008, 60, 1252-1265.
23. Verdun, C.; Couvreur, P.; Vranckx, H.; Lenaerts, V.; Roland, M. Development of a nanoparticle controlled-release formulation for human use. J. Contr. Rel. 1986, 3, 205-210.
24. Chen, T.J.; Cheng, T.H.; Chen, C.Y.; Hsu, S.C.; Cheng, T.L.; Liu, G.C.; Wang, Y.M. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J. Biol. Inorg. Chem. 2009, 14, 253-260.
25. Ho, K.M.; Li, P. Design and synthesis of novel magnetic core-shell polymeric particles. Langmuir 2008, 24, 1801-1807.
26. Zhang, Y.; Kohler, N.; Zhang, M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 2002, 23, 1553-1561.
27. Josephson, L.; Lewis, J.; Jacobs, P.; Hahn, P.F.; Stark, D.D. The effects of iron oxides on proton relaxivity. Magn. Reson. Imag. 1988, 6, 647-653.
28. Wang, A.Z.; Bagalkot, V.; Vasilliou, C.C.; Gu, F.; Alexis, F.; Zhang, L.; Shaikh, M.; Yuet, K.; Cima, M.J.; Langer, R.; Kantoff, P.W.; Bander, N.H.; Jon, S.; Farokhzad, O.C. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 2008, 3, 1311-1315.
29. Bonnemain, B. Superparamagnetic agents in magnetic resonance imaging: Physicochemical characteristics and clinical applications. A review. J. Drug Target 1998, 6, 167-174.
30. Reimer, P.; Tombach, B. Hepatic MRI with SPIO: Detection and characterization of focal liver lesions. Eur. Radiol. 1998, 8, 1198-1204.
31. Corot, C.; Robert, P.; Idee, J.M.; Port, M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev. 2006, 58, 1471-1504.
32. Loo, C.; Lin, A.; Hirsch, L.; Lee, M.H.; Barton, J.; Halas, N.; West, J.; Drezek, R. Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol. Cancer Res. Treat. 2004, 3, 33-40.
33. Harisinghani, M.G.; Saini, S.; Slater, G.J.; Schnall, M.D.; Rifkin, M.D. MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (Combidex): Preliminary observations. J. Magn. Reson Imaging 1997, 7, 161-163.
34. Fritz, J.; Baller, M.K.; Lang, H.P.; Rothuizen, H.; Vettiger, P.; Meyer, E.; Guntherodt, H.; Gerber, C.; Gimzewski, J.K. Translating biomolecular recognition into nanomechanics. Science 2000, 288, 316-318.
35. Kwon, G.S. Polymeric micelles for delivery of poorly water-soluble compounds. Crit. Rev. Ther. Drug Carrier. Syst. 2003, 20, 357-403.
36. Nishiyama, N.; Kataoka, K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther. 2006, 112, 630-648.
37. Park, J.W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 2002, 4, 95-99.
38. Sparreboom, A.; Scripture, C.D.; Trieu, V.; Williams, P.J.; De, T.; Yang, A.; Beals, B.; Figg, W.D.; Hawkins, M.; Desai, N. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res. 2005, 11, 4136-4143.
39. Gradishar, W.J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O'Shaughnessy, J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23, 7794-7803.
40. Moreno-Aspitia, A.; Perez, E.A. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. Future Oncol. 2005, 1, 755-762.
41. Bharali, D.J.; Mousa, S.A. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol. Ther. 2010, 128, 324-335.
42. Farokhzad, O.C.; Cheng, J.; Teply, B.A.; Sherifi, I.; Jon, S.; Kantoff, P.W.; Richie, J.P.; Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 2006, 103, 6315-6320.
43. Guo, X.; Szoka, F.C., Jr. Chemical approaches to triggerable lipid vesicles for drug and gene delivery. Acc. Chem. Res. 2003, 36, 335-341.
44. Iyer, A.K.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 2006, 11, 812-818.
45. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Contr. Rel. 2000, 65, 271-284.
46. Nam, H.Y.; Kwon, S.M.; Chung, H.; Lee, S.Y.; Kwon, S.H.; Jeon, H.; Kim, Y.; Park, J.H.; Kim, J.; Her, S.; Oh, Y.K.; Kwon, I.C.; Kim, K.; Jeong, S.Y. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J. Contr. Rel. 2009, 135, 259-267.
47. Jain, R.K. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1999, 1, 241-263.
48. Hirsch, L.R.; Stafford, R.J.; Bankson, J.A.; Sershen, S.R.; Rivera, B.; Price, R.E.; Hazle, J.D.; Halas, N.J.; West, J.L. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl. Acad. Sci. USA 2003, 100, 13549-13554.
49. El-Sayed, I.H.; Huang, X.; El-Sayed, M.A. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 2006, 239, 129-135.
50. Loo, C.; Lowery, A.; Halas, N.; West, J.; Drezek, R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano. Lett. 2005, 5, 709-711.
51. Fonseca, C.; Simoes, S.; Gaspar, R. Paclitaxel-loaded PLGA nanoparticles: Preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Contr. Rel. 2002, 83, 273-286.
52. Dong, Y.; Feng, S.S. Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26, 6068-6076.
53. Sun, B.; Ranganathan, B.; Feng, S.S. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 2008, 29, 475-486.
54. Win, K.Y.; Feng, S.S. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials 2006, 27, 2285-2291.
55. Avgoustakis, K.; Beletsi, A.; Panagi, Z.; Klepetsanis, P.; Karydas, A.G.; Ithakissios, D.S. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J. Contr. Rel. 2002, 79, 123-135.
56. Gryparis, E.C.; Hatziapostolou, M.; Papadimitriou, E.; Avgoustakis, K. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur. J. Pharm. Biopharm. 2007, 67, 1-8.
57. Yoo, H.S.; Lee, K.H.; Oh, J.E.; Park, T.G. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J. Contr. Rel. 2000, 68, 419-431.
58. Yoo, H.S.; Oh, J.E.; Lee, K.H.; Park, T.G. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm. Res. 1999, 16, 1114-1118.
59. Gulyaev, A.E.; Gelperina, S.E.; Skidan, I.N.; Antropov, A.S.; Kivman, G.Y.; Kreuter, J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 1999, 16, 1564-1569.
60. Manil, L.; Couvreur, P.; Mahieu, P. Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles. Pharm. Res. 1995, 12, 85-87.
61. Kojima, C.; Kono, K.; Maruyama, K.; Takagishi, T. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug. Chem. 2000, 11, 910-917.
62. Li, Y.; Cheng, Y.; Xu, T. Design, synthesis and potent pharmaceutical applications of glycodendrimers: a mini review. Curr. Drug Discov. Technol. 2007, 4, 246-254.
63. Cheng, Y.; Wang, J.; Rao, T.; He, X.; Xu, T. Pharmaceutical applications of dendrimers: promising nanocarriers for drug delivery. Front Biosci. 2008, 13, 1447-1471.
64. Bawarski, W.E.; Chidlowsky, E.; Bharali, D.J.; Mousa, S.A. Emerging nanopharmaceuticals. Nanomedicine 2008, 4, 273-282.
65. Lu, Y.; Low, P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 2002, 54, 675-693.
66. Patri, A.K.; Kukowska-Latallo, J.F.; Baker, J.R., Jr. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv. Drug Deliv. Rev. 2005, 57, 2203-2214.
67. Quintana, A.; Raczka, E.; Piehler, L.; Lee, I.; Myc, A.; Majoros, I.; Patri, A.K.; Thomas, T.; Mule, J.; Baker, J.R., Jr. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. 2002, 19, 1310-1316.
68. The Freedonia Group. Nanotechnology in Health Care; US Industry Study with Forecasts to 2011, 2016, & 2021; Study #2168; The Fredonia Group: Cleveland, OH, USA, 2007.
69. Lux Research. The Nanotech Report™2006: Investment Overview and Market Research for Nanotechnology; Lux Research: New York, NY, USA, 2006.
70. NIH. ClinicalTrials.gov. Available online: http://clinicaltrials.gov/ (accessed on July 14, 2011).